Michael Anstey

Dr. Michael Anstey is a Partner specializing in life sciences investments.

Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.

Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners.

Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.

Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Storm Therapeutics, Immutrin, PredictImmune, Sense Bio, Start Codon, and Epitopea. He is also on the board of Cambridge&, an organization dedicated to attracting the highest quality individuals and organizations from around the globe into the Cambridge ecosystem.